AUS
NZ
UK
CA
USA
IND
In a remarkable start to the week, shares of 4DMedical Ltd (ASX: 4DX) have experienced a surge of 67%, reaching 77 cents in afternoon trade on the Australian Securities Exchange (ASX). The medical technology company's stock has witnessed substantial investor interest following a significant development in the United States.
Key Catalyst: U.S. Centers for Medicare & Medicaid Services Recognition
Investors have been eager to acquire shares of 4DMedical today, prompted by a notable endorsement in the United States.
With this development, XV LVAS scans conducted in U.S. hospital outpatient facilities for Medicare patients can be billed to CMS at a rate of US$299 per scan, in coming year.
Understanding XV LVAS: A Technological Breakthrough
XV LVAS represents a groundbreaking modality, dynamically quantifying ventilation throughout the lungs. Its computed tomography-enabled counterpart software, CT LVAS, leverages the company's flagship patented XV Technology. This technology empowers physicians to gain insights into regional airflow in the lungs, enabling the early identification of respiratory deficiencies with heightened sensitivity during the breathing process.
CEO Andreas Fouras Expresses Enthusiasm: A Major Milestone
Andreas Fouras, CEO, and founder of 4DMedical, expressed his enthusiasm about the news, emphasizing the progress in commercializing their technology. He highlighted the positive impact the reimbursement decision would have on doctors and patients, considering the achievement of a Medicare reimbursement rate of US$299 per scan.
Fouras stated,
